NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA278; Omalizumab for the treatment of severe persistent allergic asthma

Final recommendation post consultation

The guidance will be transferred the 'static guidance' list.

1. Background

This guidance was issued in April 2013.

At the GE meeting of 25 February 2016 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance' list.

3. Rationale for selecting this proposal

Follow-up data from the INNOVATE study originally included in the appraisal, an additional study observing omalizumab add-on therapy and 3 systematic reviews have been published. These additional data are not inconsistent with the results used for the appraisal and would not be expected to change the decision.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Respondent: Royal College of Physicians	Comment from Technology Appraisals
Response to proposal: Agree	Comment noted. No action required.
We have liaised with The British Thoracic Society and our experts in immunology and allergy, and would like to support the proposal to move the technology appraisal to static list.	

Respondent: Royal College of Nursing	Comment from Technology Appraisals
Response to proposal: No comment	

Respondent: Novartis	Comment from Technology Appraisals
Response to proposal: Agree	Comment noted. No action required.
Novartis are in complete agreement with the proposal to move TA278 to the 'static list' of technology appraisals.	

Respondent: British Thoracic Society	Comment from Technology Appraisals
Response to proposal: Agree	Comment noted. No action required.
The British Thoracic Society supports this proposal.	

Paper signed off by:Melinda Goodall, 9th May 2016

Contributors to this paper:

Technical Lead: Caroline Hall

Project Manager: Andrew Kenyon